Catalyst Health Economics Consultants

Overactive Bladder

Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria.

Authors: JF Guest, D Abegunde & FJ Ruiz.
Source: Clinical Drug Invesigation 2004; 24 (6): 305-321.

View Abstract


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018